Sputum metagenomics of people with bronchiectasis.
Journal
ERJ open research
ISSN: 2312-0541
Titre abrégé: ERJ Open Res
Pays: England
ID NLM: 101671641
Informations de publication
Date de publication:
Mar 2024
Mar 2024
Historique:
received:
13
12
2023
accepted:
08
01
2024
medline:
6
3
2024
pubmed:
6
3
2024
entrez:
6
3
2024
Statut:
epublish
Résumé
The microbiota in the sputum of people with bronchiectasis has repeatedly been investigated in cohorts of different geographic origin, but so far has not been studied to the species level in comparison to control populations including healthy adults and smokers without lung disease. The microbial metagenome from sputa of 101 European Bronchiectasis Registry (EMBARC) study participants was examined by using whole-genome shotgun sequencing. Our analysis of the metagenome of people with bronchiectasis revealed four clusters characterised by a predominance of The gradient of depletion of commensal taxa found in healthy airways is a key feature of bronchiectasis associated with disease severity.
Sections du résumé
Background
UNASSIGNED
The microbiota in the sputum of people with bronchiectasis has repeatedly been investigated in cohorts of different geographic origin, but so far has not been studied to the species level in comparison to control populations including healthy adults and smokers without lung disease.
Methods
UNASSIGNED
The microbial metagenome from sputa of 101 European Bronchiectasis Registry (EMBARC) study participants was examined by using whole-genome shotgun sequencing.
Results
UNASSIGNED
Our analysis of the metagenome of people with bronchiectasis revealed four clusters characterised by a predominance of
Conclusion
UNASSIGNED
The gradient of depletion of commensal taxa found in healthy airways is a key feature of bronchiectasis associated with disease severity.
Identifiants
pubmed: 38444657
doi: 10.1183/23120541.01008-2023
pii: 01008-2023
pmc: PMC10910388
pii:
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
Copyright ©The authors 2024.
Déclaration de conflit d'intérêts
Conflict of interest: A. Shoemark reports consulting fees from Spirovant and Translate Bio. Conflict of interest: J.D. Chalmers reports grants or contracts from AstraZeneca, Boehringer Ingelheim, Insmed, Gilead Sciences, Novartis, Genentech, GlaxoSmithKline and Trudell; fees from AstraZeneca, Boehringer Ingelheim, Insmed, Gilead Sciences, Novartis, Genentech, GlaxoSmithKline, Trudell, Zambon, CSL Behring, Janssen and Antabio; and is an associate editor of this journal. Conflict of interest: B. Tümmler reports grants from Vertex Pharmaceuticals. Conflict of interest: All other authors have nothing to disclose.